Last reviewed · How we verify
Diagnostic Test for Growth Hormone Secretion — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| R-Gene 10 | ARGININE | Pfizer | arginine hydrochloride | Nitric oxide synthase, inducible | 1973-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Diagnostic Test for Growth Hormone Secretion
- Pfizer · 1 drug in Diagnostic Test for Growth Hormone Secretion
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Diagnostic Test for Growth Hormone Secretion:
- Diagnostic Test for Growth Hormone Secretion treatment updates — RSS
- Diagnostic Test for Growth Hormone Secretion treatment updates — Atom
- Diagnostic Test for Growth Hormone Secretion treatment updates — JSON
Cite this brief
Drug Landscape (2026). Diagnostic Test for Growth Hormone Secretion — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diagnostic-test-for-growth-hormone-secretion. Accessed 2026-06-11.
Related
- Diagnostic Test for Growth Hormone Secretion full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing